Key Takeaways
- Nvidia (NVDA) and Eli Lilly (LLY) are jointly investing up to $1 billion over five years to establish an AI co-innovation lab focused on reinventing drug discovery, with operations slated to begin in South San Francisco early this year.
- Mexican President Claudia Sheinbaum firmly rejected the notion of U.S. military intervention in Mexico, reiterating her stance against foreign military presence and emphasizing national sovereignty, despite former U.S. President Donald Trump's repeated suggestions.
- Sheinbaum announced a 50% decrease in Mexico-U.S. fentanyl trafficking over the past year, attributing it to Mexican anti-drug operations, and confirmed a bilateral security committee meeting for January 22-23.
- Nvidia (NVDA) also expanded its life sciences initiatives by collaborating with Thermo Fisher Scientific (TMO) to develop autonomous lab infrastructure and saw its BioNeMo platform adopted by other life sciences leaders.
- In European financial markets, ABN AMRO successfully priced a EUR1.75 billion debt offering in two parts, while the Bank of England sold GBP800 million in gilts with a cover-ratio of 3.19.
Mexico-U.S. Relations: Sheinbaum Rejects Intervention, Cites Fentanyl Drop
Mexican President Claudia Sheinbaum has strongly reiterated Mexico's opposition to any U.S. military intervention on its soil, emphasizing national sovereignty. She stated that Mexico does not require U.S. military aid and has consistently rejected offers from former U.S. President Donald Trump for military involvement in combating drug cartels. Sheinbaum noted that while cooperation is welcome, subordination and intervention are not, recalling historical instances where U.S. intervention led to territorial losses for Mexico.
In a significant development regarding bilateral security, Sheinbaum announced that a U.S.-Mexico security committee is scheduled to meet on January 22-23. She also reported a notable success in the fight against illicit drugs, stating that fentanyl trafficking from Mexico to the U.S. has fallen by 50% over the past year. This reduction is attributed to Mexico's anti-drug operations, with Sheinbaum highlighting increased fentanyl seizures within Mexico.
Nvidia's Multi-Billion Dollar Bet on AI in Life Sciences
Nvidia (NVDA) is making a substantial push into the healthcare and life sciences sector, announcing a landmark $1 billion co-innovation AI lab with Eli Lilly and Company (LLY). This five-year investment will establish a lab in the San Francisco Bay Area, bringing together experts from both companies to apply AI across clinical development, manufacturing, and commercial operations, with work expected to commence early this year. The collaboration aims to reinvent drug discovery by leveraging Nvidia's leadership in AI and accelerated computing with Lilly's pharmaceutical expertise.
Further solidifying its presence in the sector, Nvidia (NVDA) also announced a collaboration with Thermo Fisher Scientific (TMO) to build autonomous lab infrastructure for scalable scientific discovery. The company's BioNeMo platform, an open development platform for AI-driven biology and drug discovery, is being widely adopted by life sciences leaders to accelerate research and development. This expansion includes new AI models for RNA structure prediction and drug synthesis validation, aiming to turn scientific data into a competitive engine for discovery.
European Debt Markets See Activity from ABN AMRO and Bank of England
In European financial news, ABN AMRO successfully priced a EUR1.75 billion debt offering. The offering was structured in two parts: a EUR1 billion 3-year fixed tranche and a EUR750 million 10-year fixed tranche. This debt issuance reflects ongoing activity in the corporate bond market.
Concurrently, the Bank of England conducted a gilt sale, offloading GBP800 million in gilts. The sale registered a cover-ratio of 3.19, indicating healthy demand for the government bonds.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.